Inflammation pathways as therapeutic targets in angiotensin II induced atrial fibrillation

被引:0
|
作者
Hou, Ailin [1 ,2 ]
Shi, Dazhuo [1 ]
Huang, Hongbo [1 ]
Liu, Yuxuan [1 ]
Zhang, Ying [1 ]
机构
[1] China Acad Chinese Med Sci, Xiyuan Hosp, Cardiovasc Dept, Beijing, Peoples R China
[2] Beijing Univ Chinese Med, Xiyuan Hosp, Grad Sch, Beijing, Peoples R China
关键词
atrial fibrillation; inflammation; AngII; electrical remodelling; fibrosis; anti-inflammatory therapy; EPICARDIAL ADIPOSE-TISSUE; PULMONARY VEIN ISOLATION; ARTERY-BYPASS SURGERY; C-REACTIVE PROTEIN; STATIN THERAPY; FATTY-ACIDS; NATRIURETIC-PEPTIDE; CATHETER ABLATION; SIGNAL TRANSDUCER; SYSTEM INHIBITORS;
D O I
10.3389/fphar.2025.1515864
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Atrial fibrillation (AF), a common cardiac arrhythmia, is associated with severe complications such as stroke and heart failure. Although the precise mechanisms underlying AF remain elusive, inflammation is acknowledged as a pivotal factor in its progression. Angiotensin II (AngII) is implicated in promoting atrial remodeling and inflammation. However, the exact pathways through which AngII exacerbates AF are still not fully defined. This study explores the key molecular mechanisms involved, including dysregulation of calcium ions, altered connexin expression, and activation of signaling pathways such as TGF-beta, PI3K/AKT, MAPK, NF-kappa B/NLRP3, and Rac1/JAK/STAT3. These pathways are instrumental in contributing to atrial fibrosis, electrical remodeling, and increased susceptibility to AF. Ang II-induced inflammation disrupts ion channel function, resulting in structural and electrical remodeling of the atria and significantly elevating the risk of AF. Anti-inflammatory treatments such as RAAS inhibitors, colchicine, and statins have demonstrated potential in reducing the incidence of AF, although clinical outcomes are inconsistent. This manuscript underscores the link between AngII-induced inflammation and the development of AF, proposing the importance of targeting inflammation in the management of AF.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial
    Goette, Andreas
    Schoen, Norbert
    Kirchhof, Paulus
    Breithardt, Guenter
    Fetsch, Thomas
    Haeusler, Karl Georg
    Klein, Helmut U.
    Steinbeck, Gerhard
    Wegscheider, Karl
    Meinertz, Thomas
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2012, 5 (01): : 43 - U116
  • [42] Angiotensin II inhibition and prevention of atrial fibrillation and stroke - Editorial comment
    Bourassa, MG
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (05) : 720 - 721
  • [43] New approach in the prevention of atrial fibrillation: Role of angiotensin II antagonists
    Verdecchia, P
    Angeli, F
    Sardone, MG
    Gattobigio, R
    Emerging Pathologies in Cardiology, 2005, : 85 - 90
  • [44] The vanishing story of angiotensin II receptor blockers in the treatment of atrial fibrillation
    Goette, Andreas
    EUROPACE, 2011, 13 (04): : 451 - 452
  • [45] The role of atrial inflammation in Atrial Fibrillation
    Wu, L.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2018, 120 : 49 - 49
  • [46] The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target?
    Freestone, B
    Beevers, DG
    Lip, GYH
    JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (07) : 461 - 465
  • [47] The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target?
    B Freestone
    D G Beevers
    G Y H Lip
    Journal of Human Hypertension, 2004, 18 : 461 - 465
  • [48] Atrial fibrillation: potential therapeutic interventions in the renin-angiotensin-aldosterone system
    Dabrowski, Rafal
    Szwed, Hanna
    KARDIOLOGIA POLSKA, 2007, 65 (04) : 440 - 445
  • [49] Pharmacologic targets for atrial fibrillation
    Bhakta, Deepak
    Miller, John M.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2007, 11 (09) : 1161 - 1178
  • [50] Novel targets in atrial fibrillation
    Christ, T.
    ACTA PHYSIOLOGICA, 2014, 211 : 55 - 55